Charles S. Berkman - 01 Nov 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Former Executive Officer
Signature: /s/ Charles S. Berkman
Issuer symbol: LGND
Transactions as of: 01 Nov 2022
Transactions value $: $0
Form type: 4
Date filed: 03 Nov 2022, 21:06
Previous filing: 30 Sep 2022
Next filing: 05 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Disposed to Issuer		-11.9K	-33.39%		23.8K	01 Nov 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LGND	Employee Stock Option (right to buy)	Disposed to Issuer		-20.1K	-100%		0	01 Nov 2022	Common Stock	20.1K	$90.68	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Charles S. Berkman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2	The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.